231055 Assessing genetic association in case-control studies with unmeasured population substructure

Monday, November 8, 2010 : 1:25 PM - 1:36 PM

Yong Chen , Division of Biostatistics, University of Texas School of Public Health, Houston, TX
Kung-Yee Liang , Department of Biostatistics, Johns Hopkins University, Baltimore, MD
Terri Beaty , Department of Epidemiology, Johns Hopkins University, Baltimore, MD
Kathleen Barnes , Division of Clinical Immunology, Johns Hopkins University, Baltimore, MD
Linda Kao , Department of Epidemiology, Johns Hopkins University, Baltimore, MD
The case-control study design is one of the main tools for detecting associations between genetic markers and disease. It is well known population substructure (PS) can lead to spurious association between disease status and a genetic marker if the prevalence of disease and the marker allele frequency vary across subpopulations. In this paper, we proposed a novel statistical method to estimate the association in case-control studies with potential population substructure. The proposed method takes two steps. First, the information on genomic markers and disease status is used to infer population substructure; second, the association between disease and any one marker adjusting for the population substructure is then modeled and estimated parametrically through polytomous logistic regression. The performance of the proposed method, relative to others, on bias, coverage probability and computational time, is assessed through simulations. Finally, this method is applied to an asthma study and an end-stage renal disease study in African Americans populations.

Learning Areas:
Biostatistics, economics

Learning Objectives:
To describe a novel statistical method to estimate the association in case-control studies with potential population substructure.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am the first author of this methodological paper.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.